The stock of Cyclacel Pharmaceuticals Inc (NASDAQ: CYCC) has decreased by -29.20% when compared to last closing price of $0.34.Despite this, the company has seen a loss of -34.86% in its stock price over the last five trading days. globenewswire.com reported 2025-07-02 that BERKELEY HEIGHTS, N.J., July 02, 2025 (GLOBE NEWSWIRE) — Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; “Cyclacel” or the “Company”), a biopharmaceutical company developing innovative medicines, today announced that it expects to implement a 1-for-15 reverse stock split on its shares of common stock effective July 7, 2025, with trading to begin on a split-adjusted basis at the market open on that day.
Is It Worth Investing in Cyclacel Pharmaceuticals Inc (NASDAQ: CYCC) Right Now?
The 36-month beta value for CYCC is at -0.02. Analysts have varying views on the stock, with 0 analysts rating it as a “buy,” 0 rating it as “overweight,” 1 as “hold,” and 0 as “sell.”
The public float for CYCC is 23.76M, and currently, shorts hold a 2.50% of that float. The average trading volume for CYCC on July 02, 2025 was 1.47M shares.
CYCC’s Market Performance
CYCC’s stock has seen a -34.86% decrease for the week, with a -85.48% drop in the past month and a -94.47% fall in the past quarter. The volatility ratio for the week is 10.97%, and the volatility levels for the past 30 days are at 29.83% for Cyclacel Pharmaceuticals Inc The simple moving average for the past 20 days is -41.45% for CYCC’s stock, with a -96.23% simple moving average for the past 200 days.
Analysts’ Opinion of CYCC
Many brokerage firms have already submitted their reports for CYCC stocks, with Oppenheimer repeating the rating for CYCC by listing it as a “Outperform.” The predicted price for CYCC in the upcoming period, according to Oppenheimer is $17 based on the research report published on July 18, 2022 of the previous year 2022.
ROTH Capital, on the other hand, stated in their research note that they expect to see CYCC reach a price target of $24. The rating they have provided for CYCC stocks is “Buy” according to the report published on April 27th, 2020.
CYCC Trading at -88.15% from the 50-Day Moving Average
After a stumble in the market that brought CYCC to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -99.40% of loss for the given period.
Insider Trading
Reports are indicating that there were more than several insider trading activities at CYCC starting from Lazar David E., who sale 194,628,820 shares at the price of $0.03 back on Feb 26 ’25. After this action, Lazar David E. now owns 0 shares of Cyclacel Pharmaceuticals Inc, valued at $5,507,996 using the latest closing price.
Stock Fundamentals for CYCC
Current profitability levels for the company are sitting at:
- 604.05 for the present operating margin
- 1.29 for the gross margin
The net margin for Cyclacel Pharmaceuticals Inc stands at 397.48. The total capital return value is set at -4.13. Equity return is now at value -1949.77, with -168.60 for asset returns.
Based on Cyclacel Pharmaceuticals Inc (CYCC), the company’s capital structure generated 0.0 points at debt to capital in total, while cash flow to debt ratio is standing at -834.47. The debt to equity ratio resting at 0.0. The interest coverage ratio of the stock is -453.04.
Currently, EBITDA for the company is -12.0 million with net debt to EBITDA at 0.27. When we switch over and look at the enterprise to sales, we see a ratio of -108.36. The liquidity ratio also appears to be rather interesting for investors as it stands at 5.60.
Conclusion
In conclusion, Cyclacel Pharmaceuticals Inc (CYCC) has had a bad performance lately. Opinion on the stock among analysts is mixed, with some giving it a “buy” rating and others a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
